Related Experiment Video
Updated: Jun 30, 2026
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Antidiabetic activity of a polyherbal formulation (DRF/AY/5001)
Rahul V Mandlik1, Sandya K Desai, Suresh R Naik
1KM Kundnani College of Pharmacy, Colaba, Mumbai 400 005, India.
Indian Journal of Experimental Biology
|September 26, 2008
Summary
The herbal formulation DRF/AY/5001 demonstrates significant hypoglycemic and antioxidant effects in diabetic rats. It effectively improves glucose tolerance and pancreatic health, comparable to the drug glibenclamide.
Area of Science:
- Pharmacology and Toxicology
- Natural Product Chemistry
- Endocrinology
Background:
- Diabetes mellitus is a global health concern requiring novel therapeutic strategies.
- Herbal formulations are increasingly investigated for their potential antidiabetic properties.
- Understanding the mechanisms of action for herbal remedies is crucial for their clinical application.
Purpose of the Study:
- To evaluate the hypoglycemic and antidiabetic effects of the herbal formulation DRF/AY/5001.
- To investigate the antioxidant potential and protective effects on pancreatic tissue.
- To explore the underlying mechanisms of action, including pancreatic and extra-pancreatic pathways.
Main Methods:
- Experimental induction of hyperglycemia using epinephrine and alloxan in rats.
- Assessment of glucose tolerance, lipid peroxidation, and enzymatic antioxidants.
- Histopathological examination of pancreatic islets of Langerhans.
- Comparison of efficacy with the standard antidiabetic drug, glibenclamide.
Main Results:
- DRF/AY/5001 significantly reduced blood glucose levels in normal and hyperglycemic rats.
- The formulation exhibited potent antioxidant activity, inhibiting lipid peroxidation and enhancing antioxidant enzymes.
- Histopathological studies revealed amelioration of alloxan-induced pancreatic islet damage.
- The effects at 600 mg/kg were comparable to glibenclamide (4 mg/kg).
Conclusions:
- The herbal formulation DRF/AY/5001 possesses significant antidiabetic and antioxidant properties.
- It may act through both pancreatic and extra-pancreatic mechanisms to improve glycemic control.
- DRF/AY/5001 shows promise for managing diabetes and maintaining metabolic health.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...